Is it a good time to buy A2 Milk (ASX:A2M) shares in August 2021?

Should you give the beaten up infant formula business a second chance

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

It took a 75% tumble for the A2 Milk Company Ltd (ASX: A2M) share price to find a bottom.

After hitting an all-time high of $19.94 in late July 2020, the A2 Milk share price would fall sharply for almost 10-consecutive months, before finally bouncing off a 4-year low of $5.04.

Could August be the time to give the ex-market darling a second chance?

Child drinking milk out of a glass.

Image source: Getty Images

Is the A2 Milk share price a buy in August?

Unfortunately, the A2 Milk we all know and love might be a thing of the past.

Brokers are quite bearish about the near-term performance of the A2 Milk business.

On Tuesday, the Motley Fool reported that Credit Suisse has retained an underperform rating for the A2 Milk share price.

Its analysts think that demand for A2's products will continue to be weak and likely dampen any earnings upside in the near term.

With the A2 Milk share price closing at $6.07 on Thursday, the brokers' target price of $5.50 represents a downside of 9.3%.

China birth policy reforms

China has introduced a number of policies in recent years in an attempt to lift rapidly declining birth rates.

On 20 July, Bloomberg reported that Beijing would regulate the country's after-school tutoring sector in an effort to cut the cost of having children.

While the Australian Financial Review (AFR) last week highlighted that "half-a-million new, low-cost childcare places will be added across 150 cities" to further encourage families to have more children.

On paper, China's policies to lift birth rates sounds encouraging for A2's infant formula business.

However, rising competition in China's domestic market and consumer preferences could pose a risk to its overseas business.

The AFR quoted commentary from CSLA analyst Richard Barwick, who said that "a2 Milk's China label business – which represents 45 per cent of its infant formula revenue – is most exposed to the risk of pricing control as it operates in the ultra-premium sector."

"… it is clear that China's government is favouring domestic infant formula brands after in 2019 setting a target for local players to make up 60 per cent of consumption within three years", the AFR added.

The next catalyst for the A2 Milk share price

A2 Milk is expected to release its full year FY21 results on 26 August.

Unfortunately, A2's track record of full year results has been far from pleasant.

The company's FY19 and FY20 results witnessed a respective 13.19% and 6.53% decline on the day of the results.

Motley Fool contributor Kerry Sun has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended A2 Milk. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Broker Notes

Man sits smiling at a computer showing graphs.
Broker Notes

6 ASX 200 shares with strengthened buy ratings this week

Brokers have maintained confidence in these ASX 200 stocks amid today's volatile market conditions.

Read more »

A happy person clenching fists in celebration sitting at computer.
Broker Notes

Morgans says hold BHP shares and buy this ASX 200 stock      

Let's see what the broker is saying about these stocks this week.

Read more »

An ASX 200 market analyst holds his hand to his chin and looks closely at his computer screens watching share price movements
Broker Notes

3 ASX 200 shares just upgraded to strong buy — here's what the brokers are saying

Do any of these ASX 200 stocks appeal to you?

Read more »

Person pressing the buy button on a smartphone.
Broker Notes

3 reasons to buy Pro Medicus shares today

A leading analyst believes Pro Medicus shares are now trading at a significant discount.

Read more »

Two men look excited on the trading floor as they hold telephones to their ears and one points upwards.
Broker Notes

Buy, hold, sell: Sigma Healthcare, Macquarie, Santos shares

Brokers reveal their latest ratings and reviews on 3 ASX 200 stocks.

Read more »

A man rests his chin in his hands, pondering what is the answer?
Broker Notes

Buy, hold, sell: Macquarie, Boss Energy, CBA shares

The market looks set to endure a sixth consecutive day in the red.

Read more »

A smiling businessman in the city looks at his phone and punches the air in celebration of good news.
Broker Notes

Guess which ASX 200 share could rise 90% according to Bell Potter

Let's see what the broker is saying about this stock this week.

Read more »

Man drawing an upward line on a bar graph symbolising a rising share price.
Broker Notes

These ASX 200 shares could rise 25% to 70%

Morgans expects big returns from these top stocks.

Read more »